Tags

Type your tag names separated by a space and hit enter

Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
Biomed Pharmacother. 2020 Oct; 130:110559.BP

Abstract

As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site. Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230, 80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of interaction of RBD and different mAbs were explained and it was suggested that one of the SARS-CoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARS-CoV2 S-protein RBD. Finally, some ongoing challenges and future prospects for rapid and sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In conclusion, it may be proposed that this review may pave the way for recognition of RBD and different mAbs to develop potential therapeutic ESV.

Authors+Show Affiliations

School of Life Sciences, Manipal Academy of Higher Education, Dubai, United Arab Emirates.Department of Mechanical and Industrial Engineering, College of Engineering, Qatar University, Doha, 2713, Qatar; Biomedical Research Center, Qatar University, Doha, 2713, Qatar. Electronic address: ahasan@qu.edu.qa.Department of Molecular Genetics, Faculty of Biological Science, North Tehran Branch, Islamic Azad University, Tehran, Iran.Department of Clinical Sciences, College of Pharmacy and Health Sciences, Ajman University, PO Box 346, Ajman, United Arab Emirates.Department of Electrical Engineering, Qatar University, Doha, 2713, Qatar.Department of Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.Department of Microbiology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Electronic address: haghighat.s@iaups.ac.ir.Department of Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. Electronic address: mojtaba.alahati@alumni.ut.ac.ir.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32768882

Citation

Hussain, Arif, et al. "Targeting SARS-CoV2 Spike Protein Receptor Binding Domain By Therapeutic Antibodies." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 130, 2020, p. 110559.
Hussain A, Hasan A, Nejadi Babadaei MM, et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomed Pharmacother. 2020;130:110559.
Hussain, A., Hasan, A., Nejadi Babadaei, M. M., Bloukh, S. H., Chowdhury, M. E. H., Sharifi, M., Haghighat, S., & Falahati, M. (2020). Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 130, 110559. https://doi.org/10.1016/j.biopha.2020.110559
Hussain A, et al. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain By Therapeutic Antibodies. Biomed Pharmacother. 2020;130:110559. PubMed PMID: 32768882.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies. AU - Hussain,Arif, AU - Hasan,Anwarul, AU - Nejadi Babadaei,Mohammad Mahdi, AU - Bloukh,Samir Haj, AU - Chowdhury,Muhammad E H, AU - Sharifi,Majid, AU - Haghighat,Setareh, AU - Falahati,Mojtaba, Y1 - 2020/08/01/ PY - 2020/04/16/received PY - 2020/07/09/revised PY - 2020/07/25/accepted PY - 2020/8/10/pubmed PY - 2020/11/11/medline PY - 2020/8/10/entrez KW - Corona virus KW - antibodies KW - epitope-specific vaccines (ESV) KW - receptor binding domain KW - spike protein SP - 110559 EP - 110559 JF - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie JO - Biomed Pharmacother VL - 130 N2 - As the number of people infected with the newly identified 2019 novel coronavirus (SARS-CoV2) is continuously increasing every day, development of potential therapeutic platforms is vital. Based on the comparatively high similarity of receptor-binding domain (RBD) in SARS-CoV2 and SARS-CoV, it seems crucial to assay the cross-reactivity of anti-SARS-CoV monoclonal antibodies (mAbs) with SARS-CoV2 spike (S)-protein. Indeed, developing mAbs targeting SARS-CoV2 S-protein RBD could show novel applications for rapid and sensitive development of potential epitope-specific vaccines (ESV). Herein, we present an overview on the discovery of new CoV followed by some explanation on the SARS-CoV2 S-protein RBD site. Furthermore, we surveyed the novel therapeutic mAbs for targeting S-protein RBD such as S230, 80R, F26G18, F26G19, CR3014, CR3022, M396, and S230.15. Afterwards, the mechanism of interaction of RBD and different mAbs were explained and it was suggested that one of the SARS-CoV-specific human mAbs, namely CR3022, could show the highest binding affinity with SARS-CoV2 S-protein RBD. Finally, some ongoing challenges and future prospects for rapid and sensitive advancement of therapeutic mAbs targeting S-protein RBD were discussed. In conclusion, it may be proposed that this review may pave the way for recognition of RBD and different mAbs to develop potential therapeutic ESV. SN - 1950-6007 UR - https://www.unboundmedicine.com/medline/citation/32768882/Targeting_SARS_CoV2_Spike_Protein_Receptor_Binding_Domain_by_Therapeutic_Antibodies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0753-3322(20)30752-6 DB - PRIME DP - Unbound Medicine ER -